Sun Pharma May Be Third Time Lucky After Latest U.S. FDA Inspection
FDA’s observations are procedural and don’t point to any data integrity issues.
The three fresh observations Sun Pharmaceutical Industries Ltd. received from the U.S. drug regulator for its biggest facility in Halol, Gujarat are procedural and don’t point to any data integrity issues, two people aware of the development told BloombergQuint requesting anonymity.
That may brighten the prospects for India’s largest drugmaker as the plant, with several pending drug filings, faces restrictions on approvals in the U.S., its biggest market.
Sun Pharma declined to comment. The U.S. Food and Drug Administration, in response to emailed queries, said it will reply as soon as possible.
Inspectors from the U.S. FDA issued three observations after completing the inspection on Feb. 23. The review stems from the nine observations that the plant received in 2016. That had followed a December 2015 warning letter preventing the company from making fresh filings.
The fresh observations relate to equipment, employee training and incubation temperature, the people quoted above said. The people said the observations can be summed up as:
- Poor upkeep of equipment, especially of filling machine; rust on machines seen.
- Wrong incubation temperatures used to identify microbial growth.
- Procedural lapses including inadequate training of staff.
Shares of Sun Pharma rose as much as 1.5 percent intraday to Rs 543.5. The stock has dropped 5 percent year-to-date, and 20 percent over the last one year.
Why Halol Matters
Sun Pharma in its conference after the earnings for the quarter ended December had highlighted the continuing pricing pressures in the U.S. An all-clear for the Halol plant will help it speed up several complex generic filings and ramp up existing products in the U.S. The launch of key drugs like Xelpros for Glaucoma and Elepsia used for epilepsy, developed by Sun Pharma Advanced Research Co. Ltd., depends on the approval.
If the plant is not cleared, Sun Pharma would lose opportunities in the U.S. due to delayed drug approvals and its earnings growth will depend on a single product, according to a recent Morgan Stanley report.
The Halol plant’s contribution to the U.S. sales declined to 11 percent from 22 percent before its regulatory troubles began, according to a CLSA report. Its share in overall sales dropped from 12 percent to 4 percent.
That’s because of two reasons. The acquisition of Ranbaxy Laboratories Ltd. increased the overall base. Also, sales declined amid price erosion and competition from about $350 million to $150 million in three years through March 2017.